Hyus Meditec

Hyus Meditec operates across medical devices, diagnostics, research tools, and neurotechnology, with biomedical ultrasound as its clearest technical focus. Its described portfolio combines high-resolution imaging and programmable ultrasound with intracardiac interventional systems and non-contact ultrasonic pipetting. That mix connects clinical imaging and intervention with laboratory and life-sciences workflows, rather than limiting the company to a single ultrasound use case. The stated expertise in high-frequency ultrasound and collaborations with the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, and the State Key Laboratory of Medical Imaging provide context for its research-oriented positioning. However, the available profile does not identify named competitors, product performance benchmarks, regulatory clearances, installed base, or market share. Naming specific rival companies or asserting a competitive lead would therefore be unsupported. Its differentiators are best described as the breadth of applications and the inclusion of precision liquid handling alongside medical ultrasound, rather than proven commercial scale. Further information on product approvals, clinical evidence, customer adoption, and pricing would be needed to compare its position with established medical-imaging suppliers and specialist ultrasound developers.

The known financing history shows three rounds across June 2023, May 2025, and June 2026. The June 2023 Pre-Series A round was led by 上海科创 and described as several tens of millions of yuan. 南山创投 led the May 2025 round, for which no amount is specified, and 荷塘投资 led the June 2026 round, also described as several tens of millions of yuan. This sequence indicates continued fundraising activity over roughly three years, but the available figures do not support a reliable USD funding total or conclusions about valuation. The company’s product scope spans high-resolution and programmable ultrasound, intracardiac intervention, and non-contact ultrasonic pipetting. The 2026 financing is the latest identifiable inflection point; its impact on manufacturing, regulatory progress, or commercialization is not documented.